Download Library Categories Annual General MeetingAnnual ReportsCorporate Governance*Corporate PresentationsFact SheetInterim ReportsPodcastsResearch Presentations & PapersWebcasts Year None20192018201720162015201420132012201120102009200820072006200520042003200220012000 Document Type Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau) Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau) Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon) Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon) Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay) Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay) Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek) Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek) Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka) Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka) Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani) Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani) Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari) Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari) Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos) Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos) Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau) Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau) Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu) Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu) DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu) DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu) Q3 2016 Results Presentation Q3 2016 Results Presentation Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016 Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016 Q3 2016 Results Podcast Q3 2016 Results Podcast Interim Report First Half 2016 Interim Report First Half 2016 First Half 2016 Results Presentation First Half 2016 Results Presentation First Half 2016 Results Podcast First Half 2016 Results Podcast Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels) Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels) Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese) Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese) Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf) Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf) Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo) Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo) Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos) Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos) Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi) Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi) Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016 Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016 Interim Report First Quarter 2016 Interim Report First Quarter 2016 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
